1. Background {#s0005}
=============

Incisional carcinoma is a rare, delayed surgical complication which is attended by a generally poor prognosis. Incisional carcinoma can occur after surgery for either malignant or benign indications; in the latter case the development is most commonly attributed to the malignant transformation of either endometriosis implants invasive into the surgical scar, or to endometrial tissue displaced during gynecologic or obstetric surgery which can occur in 0.03 --1.73% of cases after cesarean section ([@b0010]).

The criteria to diagnose endometriosis-related malignancies was proposed by Sampson in 1925 and includes (1) presence of both benign and malignant endometrial tissue in the tumor, (2) histology compatible with endometrial origin, (3) no other primary tumor sites ([@b0200]). In 1953, Scott added a fourth criterion to this list: (4) demonstration of benign endometriosis contiguous with the malignant tissue ([@b0210]).

Notably, not all suspected cases meet Sampson's criteria, suggesting that even isolated incisional carcinoma may arise through variable mechanisms. When incisional carcinoma is found in the anterior abdominal wall the differential diagnosis must also include cutaneous metastasis from an ovarian, endometrial, cervical, or non-gynecologic malignancy as well as primary skin adnexal neoplasms. These differential diagnoses would have significant implications for the surgical planning and medical management of these patients.

Given the rarity of the condition, most reports have described only individual cases, making definitive comment on the etiology, evaluation, and optimal management of these patients difficult.

The primary histologic subtypes found in endometriosis-related carcinomas are clear cell carcinoma and endometrioid, though serous, mucinous, mixed, sarcoma and adenocarcinoma not otherwise specified (NOS) have been reported ([@b0170], [@b0220], [@b0030], [@b0160]). Median survival time for carcinoma arising in endometriosis is 35 months ([@b0170]), and for malignant transformation of scar endometriosis is 42 months ([@b0160]). We present a case of adenocarcinoma NOS found in a cesarean section scar. We then review the relevant literature.

2. Case presentation {#s0010}
====================

A 55-year-old perimenopausal female presented to the emergency department for a syncopal episode. She had noted bruising over her right lower abdomen that had worsened over the three days prior to presenting. Her medical and surgical histories were otherwise unremarkable except for hypertension and one cesarean section 18 years prior to presentation complicated by the development of a mass at the incision identified immediately post-operatively, which was felt to be a seroma, though it had not changed in size, shape, or symptomatology in the ensuing years. A CT scan in the emergency department demonstrated a 6.5 cm lobulated soft tissue mass in the right anterior abdominal wall with associated enhancing 4 and 5 cm masses of the right pelvic sidewall and an enhancing mass in the right inguinal region measuring 3.4 cm ([Fig. 1](#f0005){ref-type="fig"}). There were no associated findings in the other pelvic or abdominal organs. A PET scan confirmed high FDG -glucose uptake in all described lesions (SUV max ranged from 3.3 to 21.4), but failed to demonstrate additional lesions or a clear primary site ([Fig. 2](#f0010){ref-type="fig"}a, b, and c). Tumor markers were not elevated: Ca125 was 17.2, CEA was 2.0, and CA19-9 was 26.9; and her routine screening was up to date.Fig. 1CT Abdomen/Pelvis: 6.5 cm lobulated soft tissue mass in the right anterior abdominal wall.Fig. 2PET CT (A) Mass at the location of the right iliac lymph node chain measuring 4.3x4.0 cm with SUV max of 11.0 and mass of the lower right rectus mass measuring 6.6x3.4 cm with extension into the subcutaneous fat and SUV max of 21.4. (B) 3.5x.4 cm metabolically active soft tissue mass in the right inguinal region with SUV max of 10.6. (C) Small metabolically active nodule within the distal left rectus muscle just above the pubic symphysis with SUV max of 3.3.

A percutaneous biopsy of the anterior-most lesion was obtained and demonstrated malignant cells positive for CK7, PAX-8, WT-1, p53 (strong and diffuse), ER and PR. Combined with morphology, these findings were consistent with a "high-grade adenocarcinoma, favor high-grade serous carcinoma of ovarian, fallopian tube, primary peritoneal origin, or endometrial serous carcinoma." She underwent cytoreductive surgery including laparotomy, en bloc resection of anterior abdominal wall mass including the underlying fascia and a portion of the rectus muscle, resection of right inguinal, pelvic and *para*-aortic lymph nodes. Hysterectomy, bilateral salpingo-oophorectomy, and omentectomy were performed, in the absence of overt abnormalities, to exclude the gynecologic organs a primary site. Absorbable mesh was used to facilitate closure of the fascial defect. The patient recovered uneventfully from surgery.

Pathologic evaluation revealed a 6.1 cm high-grade adenocarcinoma with non-clear-cell-morphology ([Fig. 3](#f0015){ref-type="fig"} A) that was noted to be superficial to the abdominal wall fascia and muscle but unattached to the superficial skin. It was located along and within the previous cesarean section scar. Cytoarchitecturally, the tumor was more in keeping with an endometrioid morphology ([Fig. 3](#f0015){ref-type="fig"}B) with occasional areas of papillary formation ([Fig. 3](#f0015){ref-type="fig"}C). Malignant cells were positive for PAX-8 ([Fig. 3](#f0015){ref-type="fig"}D), ER, focally for p63 and p40. Cells were negative for GATA-3, calretinin, D2-40, CK5/6, synaptophysin, and chromogranin. It had metastasized to 2 of 2 right inguinal lymph nodes, and 1 of 14 right pelvic lymph nodes. The uterus, cervix, fallopian tubes, ovaries and omentum were uninvolved by neoplasm and no endometriosis was noted in any site.Fig. 3Histology of a high grade carcinoma. (A) Glandular morphology suggestive of a high-grade adenocarcinoma with nuclear pleomorphism and abnormal mitoses. (B) Glandular spaces are mostly rounded with a cribriform arrangement suggestive of endometrioid adenocarcinoma. Some of the nuclei showed prominent nucleoli. (C) Focal papillary formations were also noted. (D) Immunohistochemical staining for PAX-8 was strong and diffuse.

The possibility of a primary skin adnexal tumor was considered but was believed unlikely based on the negative staining for calretinin, D2-40 and CK5/6. The tumor morphology was also unsupportive of this possibility. We also excluded the possible origin from ectopic breast tissue (the caudal remnants of the milk ridge) based on the negative staining for GATA-3 with the strong and diffuse staining for PAX-8. The patient was referred for a full dermatologic examination and no suspicious skin lesions were identified.

After discussion of treatment options, the patient elected to receive both chemotherapy and radiation in a sandwiched fashion as previously described by our group ([@b0070]). She received 3 cycles of carboplatin AUC 6 and paclitaxel 175 mg/m^2^\--the third cycle of chemotherapy was complicated by grade 3 neutropenia, pegfilgrastim was added after a delay of 1 week. She then underwent pelvic radiation therapy (5000 cGy in 30 fractions to the pelvis with a 1000 cGy boost to the tumor bed), which she tolerated well with no unplanned treatment breaks. She experienced Acute Toxicity Profile by CTC v4.0: Grade 2 dermatitis, grade 1 diarrhea and grade 1 fatigue. She received 3 more cycles of carboplatin (AUC 6) and paclitaxel (175 mg/m^2^) with peg-filgrastim administration during each cycle.

Surveillance to date has included clinical and radiologic evaluations (CT scan of the chest, abdomen and pelvis) at the conclusion of treatment and after 3 and 6 months of surveillance. At the time of this report the patient was disease-free at 8 months from completion of therapy (13 months from presentation).

3. Discussion {#s0015}
=============

Our case demonstrates that incisional carcinoma can occur without associated findings of endometriosis and in the absence of overt or microscopic disease in the gynecologic organs. It adds to the 46 English-language prior reports of incisional carcinoma of Mullerian origin (Ovid Medline keywords: carcinoma, incision, abdominal wall, gynecologic surgical procedures) ([@b0170], [@b0220], [@b0030], [@b0160], [@b0040], [@b0245], [@b0065], [@b0180], [@b0020], [@b0185], [@b0165], [@b0085], [@b0005], [@b0015], [@b0035], [@b0045], [@b0095], [@b0100], [@b0105], [@b0110], [@b0125], [@b0115], [@b0135], [@b0145], [@b0150], [@b0155], [@b0175], [@b0195], [@b0215], [@b0235], [@b0240], [@b0075], [@b0140], [@b0205], [@b0050], [@b0055], [@b0090], [@b0130], [@b0025], [@b0060], [@b0080], [@b0190], [@b0225], [@b0230], [@b0120]). [Table 1](#t0005){ref-type="table"} summarizes these case reports, and [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"} presents the summary characteristics of the group.Table 1Details of Case Reports on Incisional Carcinoma of Mullerian Origin.PublicationPresenting symptom(s)Scar typeHistologySurgical resection extentOrgan involvement (pathology)Chemotherapy RegimenRadiation regimenTime to/location of recurrenceDeath([@b0040])MassCSClear cellMass, umbilicus, right rectus abdominus, partial pubic symphysis, bilateral external iliac LNs, uterus, cervix, fallopian tubes, ovaries1 right iliac LN, multiple left external iliac LNs6 cycles paclitaxel & carboplatin45 Gy abdominal-pelvic6 months / cervical, supraclavicular, axillary, mesenteric, inguinal, lumbar-aortic LNs22 months([@b0160])Pain, abdominal bloating/swellingCSClear cellMass, uterus, cervix, fallopian tubes, ovaries--9 cycles platinum-basedReceived, regimen unspecified----([@b0020])MassCSClear cellMass, rectus abdominus, uterus, cervix, fallopian tubes, ovariesNoneNoneNoneNo recurrence at 12 months--([@b0065])Abdominal bloating/swellingCSClear cellMass, rectus abdominus and fascia, uterus, fallopian tubes, ovaries, inguinal & pelvic lymph nodes7/14 pelvic LNs, 8/11 inguinal LNs3 cycles neoadjuvant carboplatin & paclitaxel, 3 cycles pegylated liposomal doxorubicinNone2 months / liver6 months([@b0245])PainCSClear cellMassNot evaluated3 cycles, agent unspecifiedNoneNo recurrence at 24 months--([@b0180])MassCSClear cellMassNot evaluatedNone50.4 Gy external beam----[@b0215]Pain, ulcerationCSClear cellMass, ovarian cyst, endometrium, iliac LNs2/4 iliac LNs6 cycles cisplatinum basedReceived, regimen unspecified5 monthsNo death at 7 months([@b0165])PainCSClear cellMass, uterus, cervix, fallopian tubes, ovaries, omentumNone3 cycles cisplatinWhole pelvic RT with boost to the scarNo recurrence at 5 years--([@b0125])PainCSClear cellMass, uterus, cervix, fallopian tubes, ovariesNone6 cycles paclitaxel & carboplatinNo recurrence at 8 months--([@b0035])MassCSClear cell, small serous componentMass, uterus, cervix, fallopian tubes, ovaries, omentum, peritoneal biopsiesNone3 cycles neoadjuvant carboplatin & paclitaxelNone8 months (1 LN)--([@b0015])PainCS, hysterectomy & BSO-Clear cellMassNone6 cycles taxol & carboplatin45 Gy----([@b0155]) (case 1)Not specifiedCS, BTL, Right oophorectomyClear cellMass, uterus, cervix, fallopian tubes, left ovary, omentum, left pelvic LNsNone8 cycles neoadjuvant carboplatin & paclitaxelNoneNo recurrence at 1 month--([@b0155]) (case 2)Not specifiedCS, hysterectomyClear cellMass, fallopian tubes, ovaries, omental biopsyNoneNone50.4 Gy to right abdomenNo recurrence at 31 months--([@b0240])PainCSClear cellMass, uterus, cervix, fallopian tubes, ovaries, omentum, bilateral pelvic and inguinal LNs10/14 pelvic LNs, 17/17 inguinal LNs; left ovarian dermoid, cervical CIN34 cycles carboplatin & paclitaxel (refused 2 more cycles)None3 months11 months([@b0005])PainMyomectomyClear cellMass, endometrial biopsyNoneNoneNone6 months--([@b0085])PainMini-laparotomy BTLClear cellMass, peritoneal washingsNoneNone10 fractions to scarNo recurrence at 18 months--[@b0105]MassCSClear cellMassNot evaluatedCisplatin-based chemotherapyNone--2 years([@b0135])Pain, abdominal bloating/swellingHysterotomy abortionMucinousMassNot evaluatedNone5500 rads to the abdominal field, 1600 rads to the pelvic field----([@b0145])Pain, abdominal bloating/swellingEndometrioma resectionClear cellMass, uterus, cervix, fallopian tubes, ovaries, omentum, pelvic LNsNone6 cycles docetaxel & carboplatinNone18 months--([@b0150])PainCSCystadeno-carcinomaMass, endometrial biopsyNoneNoneNoneNo recurrence at 18 months--[@b0235]Pain, ulcerationCSClear cellMassNot evaluatedNoneNone----[@b0045]PainCSEndometrioid, serousMass, endometrial biopsy, left iliac LNs2/2 left iliac LNs6 cycles carboplatin & paclitaxelNoneNo recurrence at 15 months--([@b0115])PainCSEndometrioid, sarcomaMass, uterus cervix, fallopian tubes, ovariesNone1 cycle cisplatin & ifosfamideNone2 months17 months([@b0195])PainAbdominal hysterectomy, salpingectomyClear cellMassNot evaluatedNoneNone----[@b0175]MassLaparotomy for uterine perforationPapillary serousMass, uterus, cervix, fallopian tubes, ovariesNone3 cycles neoadjuvant platinum-based chemotherapy, "postoperative chemotherapy"Received, regimen unspecifiedNo recurrence at 12 months--[@bib246]PainCSAdenocarcinomaMass, uterus, cervix, fallopian tubes, ovaries, omentum, pelvic paraaortic and inguinal LNs11/18 pelvic LNs, 1/9 *para*-aortic LNs, 2/5 inguinal LNs3 cycles neoadjuvant carboplatin & paclitaxel, 3 cycles carboplatin & paclitaxelNoneRecurrence at 4 months--([@b0110])Not specifiedCSAdenocarcinomaMassNot evaluatedNoneNone6 months--Razzouk et al. 2006MassCSClear cell, endometrioidMass, anterior abdominal wall LN, fallopian tubes, ovaries1/1 anterior abdominal wall LN4 cycles carboplatin & paclitaxelNone3 months6 months([@b0095]) (Case B)PainCSClear cellMass, uterus, cervix, fallopian tubes, ovariesNone; uterine adenomyosis, left ovarian follicular cystNoneNoneNo recurrence at 30 months--[@b0140]PainCSEndometrioidMassNot evaluatedNoneNoneNo recurrence at 24 months--([@b0075])PainCS, hysterectomyEndometrioidMass, ovariesNone--------([@b0205])PainCSClear cellMass, partial bladder, right rectusNot evaluated4/6 cycles carboplatin & paclitaxelNone----Stevens et al. 2013MassCSClear cell & endometrioidMass, uterus, fallopian tubes, ovaries, pelvic LNs, omentumNone3 cycles neoadjuvant carboplatin & paclitaxelRT to abdominal field----([@b0225])Not SpecifiedCSendometrioid----Neoadjuvant carboplatin & paclitaxel, adjuvant carboplatin & paclitaxelNoneNo recurrence at 17 months--Al ([@b0055])PainCSClear cellMass, uterus, fallopian tubes, ovaries, omentum, peritoneal samplesNone--------([@b0080])MassCS x2Clear cellMass, uterus, fallopian tubes, ovaries, omentum, pelvic washingsNone6 cycles carboplatin & paclitaxelNone24 months31 months([@b0090])MassCS x3Clear cellMass, left fallopian tube, left ovary, pelvic LNsBilateral pelvic LNsNoneNone5 months--([@b0060])PainCS, appendectomySerousMass, fallopian tubes, ovaries, omentum, iliac LNs, endometrial biopsy2 right and 1 left iliac LNs6 cycles carboplatin & paclitaxelNoneNo recurrence at 48 months--([@b0130])PainCSClear cellMass, partial bladder, uterus, fallopian tubes, ovaries, omentectomy, inguinal/pelvic/*para*-aortic LNsBladder, 8/8 inguinal LNs, 18/21 pelvic LNs, 6/6 *para*-aortic LNs3 cycles carboplatin & paclitaxel\
Traditional Chinese herbal medicineNone10 months12 months[@b0050]PainCSClear cellMass, endometrial biopsyNone; endometrial polypsDienogestNone----([@b0025])MassCS, LAVHClear cellMass, fallopian tubes, ovaries, omentum, pelvic and *para*-aortic LNs2/48 LNs6 cycles carboplatin & paclitaxelNoneNo recurrence at 10 months--([@b0230])PainCS, myomectomyEndometrial stromal sarcomaMass, uterus, fallopian tubes, ovariesNone--------([@b0100])MassCS x2Clear cellMassNot evaluatedNoneNone8 monthsNo death at 23 months[@bib247]PainCSClear cellMass, uterus, fallopian tubes, ovaries, omentum, pelvic washings, "staging"None3 cycles epirubicin, cyclophosphamide, cisplatinNoneNo recurrence at 14 months--([@b0190]) (Report 1)PainCSClear cellMass, uterus, fallopian tubes, ovaries, partial omentum, pelvic washingsNone; uterine adenomyosis, subserosal fibroids, left hydrosalpinx & salpingitis6 cycles carboplatin & paclitaxel--6 months--([@b0190]) (Report 2)PainCS x3, tubal ligationClear cellMass, uterus, fallopian tubes, ovaries, bilateral inguinal & internal iliac LNs, ileal & cecal nodules1 inguinal LN, 1 internal iliac LN6 cycles carboplatin & paclitaxelRT to positive pubic symphysis margin----Table 2Demographic features of reported cases.DemographicMedian (range)Age at diagnosis, N = 47 (years)47 (37--60)Interval since first surgery, N = 41 (years)18 (15--24)Time to recurrence, N = 16 (months)6 (2--24)Time to death, N = 8 (months)14.5 (6--31)Table 3Characteristics of reported cases.CharacteristicN (%)Lymph node involvement12/15 (LN assessment done; 80%)  Histologic typeClear cell32 (69.6%)Endometrioid3 (6.6%)Serous2 (4.3%)Mucinous1 (2.2%)Mixed5 (10.9%)Adenocarcinoma not otherwise specified3 (6.6%)  Scar typeCesarean section (CS)32 (69.6%)Endometriosis Resection1 (2.2%)Hysterectomy1 (2.2%)Laparotomy with uterine/adnexal procedure4 (8.7%)CS + other procedure8 (17.4%)  Adjuvant treatmentChemotherapy alone20 (43.5%)Radiation alone4 (8.7%)Chemotherapy & Radiation8 (17.4%)Hormone therapy1 (2.2%)None10 (21.7%)Not reported3 (6.6%)

3.1. Origin {#s0020}
-----------

Primary incisional carcinoma (PIC), that is without overt alternative primary, likely develops by either the malignant transformation of established endometriosis or by the inadvertent surgical translocation of benign endometrial gland cells followed by malignant transformation. While malignant transformation of endometriosis is well described, the current case describes incisional carcinoma in the absence of associated endometriosis or prior malignancy, suggesting the translocation of benign tissue followed by delayed malignant transformation. This hypothesis is supported by the absence of associated pathology in the gynecologic organs, the long latency from antecedent surgical event (cesarean section 18 years prior), and the lateralized lymphatic spread pattern which is reminiscent of vulvar cancer rather than typical intra-abdominal metastatic spread patterns.

Supporting evidence for the translocation hypothesis in our literature review includes that over 90% of patients with PIC had previously undergone procedures with possible endometrial exposure (89% cesarean section and 4% myomectomy). By comparison only 11% had prior hysterectomy and no cases were reported to have followed adnexal surgery alone. The median time interval from potentially-translocating surgery to presentation (N = 41) was 18 years (interquartile range, IQR 15,24) with \> 90% of patients having an interval of at least 10 years, which greatly exceeds the anticipated progression-free interval of a missed diagnosis of cancer at the time of primary surgery.

3.2. Presentation {#s0025}
-----------------

Patient and demographic characteristics are listed in [Table 1](#t0005){ref-type="table"}. The most common presenting symptoms of PIC in the literature review were pain (29/46, 63%) and mass (12/46, 26%). Ulceration of the skin was rare (4%).

As with our patient, most lesions are clinically palpable. Incisional mass size was reported in 45/47 cases with the median longest dimension being 8 cm (IQR 6,10). Clinical assessment of the inguinal lymph nodes was reported in 20/46 patients with 7/20 (35%) cases demonstrating overt lymphadenopathy.

Serum CA125 levels were obtained in 25/47 patients and were subtly to notably elevated in most; median 57 (IQR 22--96, Range 6--1690). CEA was reported in 10/47 cases but was within normal range in all but one case.

3.3. Evaluation and primary treatment {#s0030}
-------------------------------------

Clinical evaluation should be directed to defining the extent of disease and excluding an alternate primary. It should begin with clinical evaluation of the incision and the inguinal lymph nodes. Computed tomography (CT) or PET scan is appropriate to evaluate for alternate primary as well as to exclude distant/unresectable disease.

Primary complete surgical resection is recommended when feasible, including evaluation of the inguinal nodes given the lower anterior abdominal wall primarily drains into the inguinal nodes ([@b0120]). Either primary surgery or neoadjuvant chemotherapy followed by interval cytoreduction was attempted in all 47 reported cases. Resection of the primary tumor with at least one nodal basin evaluation was performed in 16/46 (34.8%) cases ([table 4](#t0020){ref-type="table"}). Nodal metastases were identified in 13/16 (81%) of cases when performed. In cases where no nodes were removed 20/31 cases reported follow-up; there were 8 recurrences diagnosed at a median of 7 months (range 2--24 months), and 12 patients remained without evidence of disease after follow-up of 8--60 months. Taken together, these data suggest that lymph node involvement is common, even when clinically non-suspicious, and suggests that some lymph node assessment is important to staging and treatment planning.Table 4Primary surgical strategy of reported cases.Primary surgical strategyN (%) Total N = 46Excision of primary tumor alone14 (30.4%)Evaluation/excision of at least one nodal basin16 (34.8%)Excision of additional structures[\*](#tblfn1){ref-type="table-fn"}9 (19.6%)Excision of tumor, inguinal nodes and additional structures[\*](#tblfn1){ref-type="table-fn"}7 (15.2%)[^1][^2]

Of the 46 total cases, 32 (69.6%) were clear cell carcinoma, three (6.6%) endometrioid, two (4.3%) serous, one (2.2%) mucinous, one (2.2%) endometrial stromal sarcoma, five mixed (1 clear/serous, 1 endometrioid/serous, 2 clear/endometrioid, 1 endometrioid/sarcoma; 10.9%), and three (6.6%) adenocarcinoma not otherwise specified (NOS).

3.4. Adjuvant treatment and prognosis {#s0035}
-------------------------------------

There is no current standard of care for treatment of PIC which was reflected by the variability of treatments in our review of the literature. Twelve of the 46 patients (26%) were treated with adjuvant radiation therapy; of these 6 had reported follow-up. Two of these 6 patients (33%) recurred at a median of 5.5 months, while 4 remained without evidence of disease at a median of 24.5 months (range 12--60). Thirty-four patients (74%) had no adjuvant radiation, of which follow-up data was available on 27. Of these 15 (56%) recurred at a median of 6 months (range 2--24 months); of these 7/15 (47%) died of disease at a median of 12 months (range 6--31 months). Twelve of the 27 patients (44%) without radiation were without evidence of disease at a median of 16 months (range 1--48 months).

Twenty-nine patients were treated with adjuvant chemotherapy. Follow up data was available for 23 patients; of these 13 (57%) recurred at a median of 5.5 months (range 2--24 months). Eight of 9 patients (89%) with a reported final disposition had died of their disease at a median of 14.5 months (range 6--31 months). Eighteen of the 46 patients received no adjuvant chemotherapy. Follow-up data as available on 10/18 patients; of these 4 patients experienced recurrence at a median of 6 months (range 5--8 months), while 6 patients remained without evidence of disease at a median of 21 months (range 12--31 months).

Eight patients (exclusive of the present case) were treated with both chemotherapy and radiation. Follow-up data as available on 4/8 patients; 2 recurred at 5 and 6 months respectively, 1 of whom succumbed to disease at 22 months and one who was alive with disease after 7 months. Two of the 4 patients (50%) remained without evidence of disease at 12 and 60 months respectively.

Lymphatic metastases were associated with a particularly poor prognosis. Thirteen of 16 patients (81%) who underwent lymph node dissection had inguinal or pelvic lymph node metastases. All patients with lymph node metastases were referred for adjuvant chemotherapy. Follow up data was available on 11 of these patients; 8 patients (73%) recurred at a median of 5 months (range 2--10 months) with 4/8 (50%) dying of disease at a median of 11.5 months (range 6--22 months). Three patients with nodal metastases were alive without disease at a median of 15 months (range 10--48 months).

4. Conclusions {#s0040}
==============

Incisional carcinoma is a rare but serious complication of surgery. There appears to be at least two mechanisms by which this condition occurs: translocation of benign endometrial tissue, up to decades prior to malignant transformation, and malignant transformation of endometriosis. Irrespective of the origin, diagnosis appears to be delayed with most lesions being clinically palpable at diagnosis illustrating the importance of maintaining a high index of suspicion and suggesting a potential role for earlier evaluation of persistent incisional masses. Lymph node metastases are common and appear to follow a vulvar distribution suggesting evaluation of the inguinal and pelvic lymph nodes basins appears indicated, especially in light of what appears to be a significant detriment to prognosis when nodal metastases are identified. No adjuvant treatment strategy demonstrated clear superiority in review of the literature, with a majority of patients relapsing within 6 months of completing adjuvant therapy; there were however long-term survivors in each treatment strategy. Further research is clearly needed to elucidate the etiology of this condition as well as to optimize treatment.
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[^1]: Extent of resection not available for 1 patient and not included.

[^2]: Includes any pelvic or abdominal organs.
